Literature DB >> 19713289

Determinants of left ventricular mass and hypertrophy in hemodialysis patients assessed by cardiac magnetic resonance imaging.

Rajan K Patel1, Scott Oliver, Patrick B Mark, Joanna R Powell, Emily P McQuarrie, James P Traynor, Henry J Dargie, Alan G Jardine.   

Abstract

BACKGROUND AND OBJECTIVES: Left ventricular hypertrophy (LVH) is an independent risk factor for premature cardiovascular death in hemodialysis (HD) patients and one of the three forms of uremic cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a volume-independent technique to assess cardiac structure. We used CMR to assess the determinants of left ventricular mass (LVM) and LVH in HD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 246 HD patients (63.8% male; mean age 51.5 +/- 12.1 yr) underwent CMR on a postdialysis day. LVM was measured from a stack of cine loops and indexed for body surface area (LVM index [LVMI]). Demographic, past biochemical, hematologic, and dialysis data were collected by patient record review. Results up to 180 d before CMR were collected. LVH was defined as LVMI >84.1 g/m(2) (male) or >76.4 g/m(2) (female).
RESULTS: A total of 157 (63.8%) patients had LVH. LVH was more common in patients with higher predialysis systolic BP, predialysis pulse pressure, and calcium-phosphate product (Ca X PO4). Furthermore, LVH was significantly associated with higher end-diastolic and systolic volumes and lower ejection fraction. There were positive correlations with LVMI and end-diastolic and systolic volumes. There were weak positive correlations among LVMI, mean volume of ultrafiltration, and Ca X PO4. Using multivariate linear and logistic regression (entering one BP and cardiac variable), the independent predictors of LVMI and LVH were end-diastolic volume, predialysis systolic BP, and Ca X PO4.
CONCLUSIONS: The principal determinants of LVM and LVH in HD patients are end-diastolic LV volume, predialysis BP, and Ca X PO4.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713289      PMCID: PMC2736694          DOI: 10.2215/CJN.03350509

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

1.  Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging.

Authors:  G A Stewart; J Foster; M Cowan; E Rooney; T McDonagh; H J Dargie; R S Rodger; A G Jardine
Journal:  Kidney Int       Date:  1999-12       Impact factor: 10.612

Review 2.  Assessment of left ventricular mass by cardiovascular magnetic resonance.

Authors:  Saul G Myerson; Nicholas G Bellenger; Dudley J Pennell
Journal:  Hypertension       Date:  2002-03-01       Impact factor: 10.190

3.  Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences.

Authors:  Khaled Alfakih; Sven Plein; Holger Thiele; Tim Jones; John P Ridgway; Mohan U Sivananthan
Journal:  J Magn Reson Imaging       Date:  2003-03       Impact factor: 4.813

4.  Profile of interdialytic blood pressure in hemodialysis patients.

Authors:  Sergio F F Santos; Roger B Mendes; Carlos A Santos; David Dorigo; Aldo J Peixoto
Journal:  Am J Nephrol       Date:  2003 Mar-Apr       Impact factor: 3.754

5.  Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study.

Authors:  Gérard M London; Bruno Pannier; Alain P Guerin; Jacques Blacher; Sylvain J Marchais; Bernadette Darne; Fabien Metivier; Hassan Adda; Michel E Safar
Journal:  J Am Soc Nephrol       Date:  2001-12       Impact factor: 10.121

Review 6.  Premature cardiovascular disease in chronic renal failure.

Authors:  C Baigent; K Burbury; D Wheeler
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

7.  Association between extracellular water, left ventricular mass and hypertension in haemodialysis patients.

Authors:  Riccardo Maria Fagugli; Paolo Pasini; Giuseppe Quintaliani; Franca Pasticci; Giovanni Ciao; Beatrice Cicconi; Daniela Ricciardi; Paola Vittoria Santirosi; Emanuela Buoncristiani; Francesca Timio; Fabrizio Valente; Umberto Buoncristiani
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

8.  Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy.

Authors:  Kai Ming Chow; Cheuk Chun Szeto; Leo Chi-Chiu Kum; Bonnie Ching Ha Kwan; Terence Ming-Kit Fung; Teresa Yuk-Hwa Wong; Chi Bon Leung; Philip Kam-Tao Li
Journal:  J Nephrol       Date:  2003 Nov-Dec       Impact factor: 3.902

9.  Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients.

Authors:  Kosaku Nitta; Takashi Akiba; Keiko Uchida; Shigeru Otsubo; Yuriko Otsubo; Takashi Takei; Tetsuya Ogawa; Wako Yumura; Takashi Kabaya; Hiroshi Nihei
Journal:  Hypertens Res       Date:  2004-01       Impact factor: 3.872

Review 10.  Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome.

Authors:  Charles A Herzog
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

View more
  25 in total

Review 1.  Screening for cardiovascular disease before kidney transplantation.

Authors:  Sneha Palepu; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2015-12-24

2.  The effects of frequent hemodialysis on left ventricular mass, volumes, and geometry.

Authors:  Rakesh K Mishra; Ruth F Dubin
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 8.237

3.  Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials.

Authors:  Christopher T Chan; George A Kaysen; Gerald J Beck; Minwei Li; Joan Lo; Michael V Rocco; Alan S Kliger
Journal:  Am J Nephrol       Date:  2018-04-05       Impact factor: 3.754

4.  The Association of Pre-Kidney Transplant Dialysis Modality with de novo Posttransplant Heart Failure.

Authors:  Colin R Lenihan; Sai Liu; Medha Airy; Carl Walther; Maria E Montez-Rath; Wolfgang C Winkelmayer
Journal:  Cardiorenal Med       Date:  2021-09-02       Impact factor: 4.360

Review 5.  Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations.

Authors:  Jonathan P Law; Luke Pickup; Davor Pavlovic; Jonathan N Townend; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2022-09-22       Impact factor: 2.877

6.  Correlates of left ventricular mass in chronic hemodialysis recipients.

Authors:  Ron Wald; Marc B Goldstein; Rachel M Wald; Ziv Harel; Anish Kirpalani; Jeffrey Perl; Darren A Yuen; Myles S Wolf; Andrew T Yan
Journal:  Int J Cardiovasc Imaging       Date:  2013-11-30       Impact factor: 2.357

7.  Effect of Low-Sodium versus Conventional Sodium Dialysate on Left Ventricular Mass in Home and Self-Care Satellite Facility Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Mark R Marshall; Alain C Vandal; Janak R de Zoysa; Ruvin S Gabriel; Imad A Haloob; Christopher J Hood; John H Irvine; Philip J Matheson; David O R McGregor; Kannaiyan S Rabindranath; John B W Schollum; David J Semple; Zhengxiu Xie; Tian Min Ma; Rose Sisk; Joanna L Dunlop
Journal:  J Am Soc Nephrol       Date:  2020-03-18       Impact factor: 10.121

8.  Diastolic dysfunction in end-stage renal disease patient: what the ticking clock has told us?

Authors:  Chia-Ter Chao
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation.

Authors:  Kathryn K Stevens; Emily P McQuarrie; William Sands; Dianne Z Hillyard; Rajan K Patel; Patrick B Mark; Alan G Jardine
Journal:  Int J Nephrol       Date:  2011-08-09

10.  Body Mass Index or Microalbuminuria, Which One is More Important for the Prediction and Prevention of Diastolic Dysfunction in Non-diabetic Hypertensive Patients?

Authors:  Hasan Shemirani; Alireza Khosravi; Rohola Hemmati; Mojgan Gharipour
Journal:  Int J Prev Med       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.